Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Georges Pompidou European Hospital, Paris, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Paris
Treatments:ChemotherapyHospital:Georges Pompidou European Hospital
Drugs:Journal:Link
Date:May 2005

Description:

Patients: This Phase II study enrolled 130 men, who were randomized into three groups. Group B had 42 men (median age 68) with hormonal-resistant prostate cancer. In 39 patients, metastatic sites involved up to two organs; the remaining three patients had metastatic sites in three or more organs. Metastatic sites included bone and lymph node tissue.

Treatment: The treatment for group B involved three chemotherapeutic agents: docetaxel (intravenous), estramustine (oral), and prednisone.

Toxicities: Grade 3-4 toxicities in group B included thrombocytopenia and thrombosis.

Results: For group B, the overall median survival was 18.4 months.

Support: Authors of this study had been employees, consultants, or honorarium recipients for Aventis. Aventis manufactures docetaxel.

Correspondence: Stephane Oudard, MD.





Back